HUYA Bioscience International Dr. Mireille Gillings Named Pharma Executive of the Year at the BioPharma Industry Awards 2016

Recognized for Visionary Leadership Within Asia’s Pharmaceutical Industry

San Diego, CA, USA – March 24, 2016HUYA Bioscience International (HUYA) Founder and Executive Chair Mireille Gillings, Ph.D., has been named Pharma Executive of the Year at the BioPharma Industry Awards 2016. Presented in conjunction with the 9th BioPharma Asia Convention 2016.

Read more

HUYA Bioscience International Celebrates 10 Years in China

Biopharma Company with Joint HQ in Shanghai & San Diego Commemorates a Decade of Innovation

Shanghai, China – March 22, 2016HUYA Bioscience International (HUYA) celebrated the 10th anniversary of the opening of its first offices in China with a gala dinner at the ‘M on the Bund’ restaurant in Puxi, Shanghai. Executives commemorated a decade of leadership in enabling and accelerating the global development of novel biopharmaceutical product opportunities originating in China. Read more

HUYA Bioscience International Acquires Exclusive Rights to Immuno-Oncology Products from Fudan University

Inhibitors of indoleamine 2,3-dioxygenase to be Developed for Oncology Therapy

San Diego, CA, USA – March 15, 2016HUYA Bioscience International (HUYA), the leader in accelerating global development of China’s pharmaceutical innovations, today announced it has signed an exclusive license with Fudan University for the ex-China rights to a series of novel immuno-oncology drug candidates discovered by Fudan researchers.

Read more

HUYA Bioscience International Grants an Exclusive License for HBI-8000 in Japan and Other Asian Countries to Eisai

Eisai to commercialize HUYA’s Product in Lymphoma and Develop New Indications in Solid Tumors

San Diego, CA, USA – February 1, 2016HUYA Bioscience International (HUYA) President, CEO, Executive Chairman & Founder Dr. Mireille Gillings announced that Eisai Co., Ltd. has acquired from HUYA an exclusive license agreement for HBI-8000 in Japan, South Korea, Thailand, Malaysia, Indonesia, Philippines, Vietnam and Singapore.

Read more



美国加州圣迭戈 – 2016年2月1日  –沪亚生物国际总裁、首席执行官、执行董事长和创始人Mireille Gillings博士宣布,日本卫材株式会社经由协议获得了HBI-8000在日本、韩国、泰国、马来西亚、印尼、菲律宾、越南和新加坡的独占许可。 Read more